When Maziar Mike Doustdar <a href="https://www.wsj.com/health/pharma/novo-nordisk-strategy-weight-loss-drugs-9a7c7b8a?mod=WSJ_TJPOD">took over as CEO of Novo Nordisk</a> last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with<a href="https://www.wsj.com/news/author/jessica-mendoza?mod=WSJ_TJPOD"> Jessica Mendoza </a>about his plans to turn the company around, <a href="https://www.wsj.com/health/pharma/wegovy-maker-novo-nordisk-lifts-guidance-following-strong-launch-of-weight-loss-pill-07d495be?mod=WSJ_TJPOD">the recent success of their Wegovy pill </a>and what keeps him up at night. 
Further Listening: - <a href="https://open.spotify.com/episode/5pZZUVZN5869wrOqCxRYri?si=995964c2fe3d4bf8">Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?</a>
- <a href="https://open.spotify.com/playlist/0qijsxLd9QvGe3cwWBNAwk?si=f4f959a025e14127">Trillion Dollar Shot</a> 
Sign up for WSJ’s free <a href="https://www.wsj.com/newsletters/whats-news?mod=WSJ_TJPOD">What’s News newsletter</a>.
 Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices">megaphone.fm/adchoices</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Novo Nordisk's CEO Has a Comeback Plan

The Journal.

AI Chapters

AI Insights

Reviews